文献速递泌尿生殖技术与安全PETCT

[68Ga]Ga-成纤维细胞激活蛋白抑制剂-04 PET/CT在肾细胞癌中的初步研究

A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma.
PubMed 文献 · Br J Radiol · 2024-01-01

本研究纳入22例疑似或复发肾细胞癌患者,其中17例确诊肾细胞癌并接受[68Ga]Ga-FAPI-04 PET/CT,6例同时接受[18F]FDG PET/CT。结果显示[68Ga]Ga-FAPI-04 PET/CT对肾细胞癌的阳性检出率为64.7%(11/17),在同时接受两种检查的6例患者中检出率高于[18F]FDG PET/CT(83.3% vs. 50%,P=0.545),且肿瘤/本底比值更高(P=0.028)。作者认为[68Ga]Ga-FAPI-04 PET/CT在肾细胞癌诊断中具有潜在价值,需进一步研究验证。

要点

  • [68Ga]Ga-FAPI-04 PET/CT对肾细胞癌的阳性检出率为64.7%(11/17)。
  • 同时行两种检查的6例中,[68Ga]Ga-FAPI-04 PET/CT检出率83.3%(5/6),[18F]FDG PET/CT为50%(3/6),P=0.545。
  • [68Ga]Ga-FAPI-04 PET/CT的肿瘤/本底比值高于[18F]FDG PET/CT(P=0.028)。

核心结论

  • 这些发现提示[68Ga]Ga-FAPI-04 PET/CT在肾细胞癌诊断中具有潜在价值,需进一步研究验证这些结果。

研究设计与样本

  • 前瞻性初步研究,纳入22例疑似或复发肾细胞癌患者,其中14例新诊断、3例复发、5例因良性肾肿瘤被排除进一步分析;17例肾细胞癌患者接受[68Ga]Ga-FAPI-04 PET/CT,其中6例同时接受[18F]FDG PET/CT;中位年龄60.5岁(四分位距54-70岁)。

诊断标准与关键数值

  • [68Ga]Ga-FAPI-04 PET/CT对肾细胞癌的阳性检出率为64.7%(11/17)。
  • 在同时接受两种检查的6例肾细胞癌患者中,[68Ga]Ga-FAPI-04 PET/CT阳性检出率为83.3%(5/6),[18F]FDG PET/CT为50%(3/6),P=0.545。
  • [68Ga]Ga-FAPI-04 PET/CT的SUVmax为3.20(四分位距2.91-5.80),[18F]FDG PET/CT为2.71(四分位距2.13-3.10),P=0.116。
  • [68Ga]Ga-FAPI-04 PET/CT的肿瘤/本底比值为1.60(四分位距1.33-3.67),[18F]FDG PET/CT为0.86(0.48-1.21),P=0.028。

局限性

  • 需进一步研究验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: As a promising positron emission tomography (PET) tracer, [68Ga]Ga-fibroblast activation protein inhibitor-04([68Ga]Ga-FAPI-04) performs better than 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) at diagnosing primary and metastatic lesions in patients with various types of cancer. We investigated the utility of [68Ga]Ga-FAPI-04 PET/CT for the detection of primary and metastatic lesions in renal cell carcinoma (RCC). [18F]FDG PET/CT were used for comparison.

METHODS: Twenty-two patients with suspected RCC or recurrent RCC were enrolled in our study. Among these patients, 14 were newly diagnosed with RCC, 3 had recurrent RCC, and 5 were excluded from further analysis due to having benign renal tumours. Seventeen patients with RCC underwent [68Ga]Ga-FAPI-04 PET/CT, and 6 of them also received [18F]FDG PET/CT. The positive detection rates were calculated and compared with those in patients who underwent both scans.

RESULTS: Data from 17 patients with RCC (median age: 60.5 years, interquartile range [IQR]: 54-70 years) were evaluated. The positive detection rate of [68Ga]Ga-FAPI-04 PET/CT for RCC was 64.7% (11/17). Lymph node metastases (n = 44), lung metastasis (n = 1), and bone metastasis (n = 1) were detected. Six patients with RCC underwent [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT. [68Ga]Ga-FAPI-04 PET/CT showed a higher positive detection rate than [18F]FDG PET/CT in detecting RCC (83.3% [5/6] vs. 50% [3/6], P = 0.545). Additionally, [68Ga]Ga-FAPI-04 PET/CT has higher SUVmax (3.20 [IQR: 2.91-5.80 vs. 2.71 [IQR: 2.13-3.10], P = 0.116) and tumour-to-background ratio (TBR) values (1.60 [IQR: 1.33-3.67] vs. 0.86 [0.48-1.21], P = 0.028) than [18F]FDG PET/CT.

CONCLUSIONS: These findings suggest that [68Ga]Ga-FAPI-04 PET/CT has potential value in RCC diagnosis. Further studies are warranted to validate these results.

ADVANCES IN KNOWLEDGE: Clinical utility of [68Ga]Ga-FAPI-04 in RCC remains unclear, and there are not many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI-04 in diagnosing RCC.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Guo C, Liu Y, Yang H, et al. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma. Br J Radiol. 2024. PMID: 38290775. doi:10.1093/bjr/tqae025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。